Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2023-008151 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Robert A Watson und 18 weiteren Autor:innen. Beteiligte Einrichtung: MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19, Myocarditis, Myositis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Cancer Research UK, Oxford Biomedical Research.
Abstract (Originalsprache)
We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within 1 month of receiving the initial cycle of the anti-PD-1 drug pembrolizumab. Analysis of T cell receptor repertoires from peripheral blood and tissues revealed a high degree of clonal expansion and public clones between cases, with several T cell clones expanded within the skeletal muscle putatively recognizing viral epitopes. All patients had recently received a COVID-19 mRNA booster vaccine prior to treatment and were positive for SARS-CoV2 Spike antibody. In conclusion, we report a series of unusually severe myositis and myocarditis following PD-1 blockade and the COVID-19 mRNA vaccination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
- Department of Oncology, University of Oxford, Oxford, UK.
- Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Department of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Department of Neuro Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Department of Clinical Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Förderung
- Wellcome Trust
- Cancer Research UK
- Oxford Biomedical Research
- Oxford CRUK Cancer Centre
- National Institute for Health Research
- Balliol Jowett Society
- Engineering and Physical Sciences Research Council
Zitieren
APA
Watson, R. A., Ye, W., Taylor, C. A., Jungkurth, E., Cooper, R., Tong, O., James, T., Shine, B., Hofer, M., Jenkins, D., Pell, R., Ieremia, E., Jones, S., Maldonado-Perez, D., Roberts, I. S. D., Coupe, N., Middleton, M. R., Payne, M. J., & Fairfax, B. P. (2024). Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008151
Vancouver
Watson RA, Ye W, Taylor CA, Jungkurth E, Cooper R, Tong O, et al. Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008151
BibTeX
@article{Watson2024,
author = {Watson, Robert A and Ye, Weiyu and Taylor, Chelsea A and Jungkurth, Elsita and Cooper, Rosalin and Tong, Orion and James, Tim and Shine, Brian and Hofer, Monika and Jenkins, Damian and Pell, Robert and Ieremia, Eleni and Jones, Stephanie and Maldonado-Perez, David and Roberts, Ian S D and Coupe, Nicholas and Middleton, Mark R and Payne, Miranda J and Fairfax, Benjamin P},
title = {Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2023-008151}
}
EUVIMED